FTSE MIB
33.823,62 +76,96 (+0,23%) Dow Jones
37.903,29 +87,37 (+0,23%) Nasdaq
15.605,48 -52,34 (-0,33%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
79,42 +0,42 (+0,53%) Bitcoin EUR
54.897,14 +834,11 (+1,54%)
Seer, Inc. (SEER)
Preborsa:
| Chiusura precedente | 2,0800 |
| Aperto | 2,0800 |
| Denaro | 2,1000 x 300 |
| Lettera | 2,1500 x 100 |
| Min-Max giorno | 2,0500 - 2,1600 |
| Intervallo di 52 settimane | 1,4550 - 5,6500 |
| Volume | |
| Media Volume | 528.427 |
| Capitalizzazione | 137,666M |
| Beta (5 anni mensile) | 1,65 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,3500 |
| Prossima data utili | 08 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 7,00 |
GlobeNewswireSeer to Participate in Upcoming September Investor Conferences
REDWOOD CITY, Calif., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company management will be participating in the following investor conferences: Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY. Fireside chat on Wednesday, September 13th at 12:15 p.m. Eastern Time Gilmartin Group Emerging Growth Company Showcase, Virtual. Presentation on Thursday, September
- GlobeNewswire
Seer Reports Second Quarter 2023 Financial Results
Launched Proteograph XT Assay Kit, enabling rapid proteomics and large-scale studiesREDWOOD CITY, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2023. Recent Highlights Achieved revenue of $4.0 million for the second quarter of 2023, an increase of 11% over the prior year periodLaunched the Proteograph XT Assay Kit, enablin
- GlobeNewswire
Seer to Present at the Canaccord Genuity 43rd Annual Growth Conference
REDWOOD CITY, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Canaccord Genuity 43rd Annual Growth Conference in Boston, MA. Seer’s management is scheduled to participate in a fireside chat on Thursday, August 10th at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time. A live webcast of the session will be available on
